BioNTech acquires CureVac

BioNTech has finalised its acquisition of CureVac for $1.25 billion, marking the end of an independent era for the Tübingen-based mRNA firm. Nasdaq confirmed the timeline for delisting CureVac’s shares, ceasing trading on January 5, 2026, and completing the formal merger process on January 6. This development provides investors limited time to adjust their positions before the compulsory conversion of their CureVac shares into BioNTech American Depositary Shares (ADS).

Under the terms of the deal, CureVac shareholders will receive 0.05363 BioNTech ADS for each CureVac share they own. With BioNTech already holding 86.75% of CureVac stock, the remaining shareholders will undergo a mandatory squeeze-out. The exchange process could incur a 15% Dutch withholding tax on the received ADS’s value. CureVac’s shares have been trading closely tied to BioNTech's share price, closing recently at $4.52, with tightly correlated market movements suggesting minimal standalone valuation influence.

Strategically, this acquisition solidifies BioNTech’s position in the mRNA domain by resolving ongoing patent disputes with CureVac concerning Covid-19 vaccine technologies. BioNTech's leadership transition includes CureVac’s former executive board stepping down, with BioNTech CEO Ugur Sahin leading the integrated operations. This consolidation is expected to enhance BioNTech’s intellectual property portfolio while potentially accelerating R&D synergies within their vaccine development pipeline.

The merger reflects broader industry trends where the biotech sector is witnessing increased consolidation driven by the need for shared expertise and resources to advance vaccine and therapeutic innovation. BioNTech’s expansion of its mRNA capabilities signals its intent to bolster its competitiveness against rivals like Moderna and Pfizer, which are also intensifying their focus on mRNA technologies.

As the deal progresses, CureVac investors will notice a transformation of their investments into BioNTech’s diversified portfolio, shifting from a single-entity speculative play to part ownership in a larger corporate entity. All technical changes will be executed automatically as per the merger terms, ensuring that investors transition smoothly into BioNTech’s equity base starting January 6, 2026.